The Roche drugs Gene Logic will reevaluate under its Drug Repositioning Program have all passed Phase I human trials but were discontinued in Phase II or Phase III trials.
Gene Logic stands to receive success-based milestone payments for each drug candidate Roche returns to clinical development, and could pocket royalties for each marketed drug, the company said.
The agreement also gives Gene Logic the option to receive an exclusive license to any drug candidate that Roche chooses not to pursue. In this case, Roche, not Gene Logic, will receive success-based milestone and royalties.
The news comes three months after Gene Logic said it would help Pfizer, the world's biggest drug maker by revenue, reposition its stalled candidates.
Gene Logic's Drug Repositioning Program, which the company outlined in March, aims to find alternative development paths for drug candidates with good safety records that have been shelved by drug makers in Phase II or Phase III clinical trials.
Gene Logic said it can complete "initial repositioning testing and analysis" in less than a year and "potentially" return drug candidates "expediently" to clinical testing.